Finding willing patients should not be hard as I would think 99% would be guided by their cardiologist, with a conversation going something like;
Well you are in luck, we have this new biomimetic valve that we are trialing that has blown existing valves out of the water with the data we have to date. Here is that comparative data so you can see for yourself. We believe this valve is going to be the valve of choice going forward, and if I were in the market for one this would be my choice.
Yeah yeah whatever you reckon Doc, you’re the man!
Ann: 30-day Haemodynamic Results from the DurAVR US EFS Trial, page-63
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.27 |
Change
0.360(6.09%) |
Mkt cap ! $97.17M | |||
| Open | High | Low | Value | Volume |
| $5.93 | $6.30 | $5.91 | $107.9K | 17.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3500 | $6.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.27 | 200 | 1 |
View Market Depth
| Last trade - 15.42pm 27/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |